使用双氢青蒿素-哌喹治疗疟疾后不明原因猝死的风险:系统综述与贝叶斯荟萃分析
该系统综述与贝叶斯荟萃分析检索至2017年5月24日,纳入94项前瞻性随机对照试验或队列研究、197 867名接受至少一个3天疗程双氢青蒿素-哌喹的个体。发现1例可能药物相关的不明原因猝死,汇总风险估计为757 950分之一(95%CI 2 854 490分之一至209 114分之一),不高于心脏性猝死基线率。作者认为对复极相关心脏毒性的担忧不必限制其当前用于疟疾预防和治疗。
要点
- 双氢青蒿素-哌喹后不明原因猝死汇总风险为757 950分之一(95%CI 2 854 490分之一至209 114分之一)。
- 该风险不高于心脏性猝死基线率(每10万人年0.7-11.9例)。
- 作者认为对复极相关心脏毒性的担忧不必限制其当前用于疟疾预防和治疗。
核心结论
- 双氢青蒿素-哌喹与不明原因猝死低风险相关,且不高于心脏性猝死基线率。
- 对复极相关心脏毒性的担忧不必限制其当前用于疟疾预防和治疗。
研究设计与样本
- 系统综述与贝叶斯荟萃分析,检索临床文献数据库至2017年5月24日,并通过WHO抗疟药心脏毒性证据审查组补充未发表研究。
- 纳入前瞻性随机对照试验或队列研究,受试者接受至少一个3天疗程双氢青蒿素-哌喹用于 масс药物 administration、预防性治疗或非复杂性疟疾病例管理,随访至少3天。
- 共纳入94项 eligible 原始研究,包含197 867名接受双氢青蒿素-哌喹的个体数据: масс药物 administration 项目中154 505人;14项重复疗程预防性治疗和非复杂性疟疾病例管理研究中15 188人;76项病例管理研究中单疗程治疗非复杂性疟疾28 174人。
主要发现
- 发现1例可能药物相关的不明原因猝死:莫桑比克一名16岁健康女性在第二剂双氢青蒿素-哌喹后数小时出现心悸,在送往医院途中倒地死亡(未进行尸检或心电图检查)。
- 双氢青蒿素-哌喹后不明原因猝死的中位汇总风险估计为757 950分之一(95%CI 2 854 490分之一至209 114分之一)。
- 该风险估计不高于心脏性猝死基线率(每10万人年0.7-11.9例,或30天风险期内1 714 280分之一至100 835分之一)。
- 大多数研究偏倚风险低,少数研究偏倚风险不明确。
关键数值与推荐
- 双氢青蒿素-哌喹后不明原因猝死中位汇总风险:757 950分之一(95%CI 2 854 490分之一至209 114分之一)。
- 心脏性猝死基线率:每10万人年0.7-11.9例,或30天风险期内1 714 280分之一至100 835分之一。
临床怎么用
- 作者认为对复极相关心脏毒性的担忧不必限制双氢青蒿素-哌喹当前用于疟疾预防和治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dihydroartemisinin-piperaquine is an effective and well tolerated artemisinin-based combination therapy that has been assessed extensively for the prevention and treatment of malaria. Piperaquine, similar to several structurally related antimalarials currently used, can prolong cardiac ventricular repolarisation duration and the electrocardiographic QT interval, leading to concerns about its proarrhythmic potential. We aimed to assess the risk of potentially lethal iatrogenic ventricular arrhythmias in individuals receiving dihydroartemisinin-piperaquine. METHODS: We did a systematic review and Bayesian meta-analysis. We searched clinical bibliographic databases (last on May 24, 2017) for studies of dihydroartemisinin-piperaquine in human beings. Further unpublished studies were identified with the WHO Evidence Review Group on the Cardiotoxicity of Antimalarials. We searched for articles containing "dihydroartemisinin-piperaquine" as title, abstract, or subject heading keywords, with synonyms and variant spellings as additional search terms. We excluded animal studies, but did not apply limits on language or publication date. Eligible studies were prospective, randomised, controlled trials or cohort studies in which individuals received at least one 3-day treatment course of dihydroartemisinin-piperaquine for mass drug administration, preventive therapy, or case management of uncomplicated malaria, with follow-up over at least 3 days. At least two independent reviewers screened titles, abstracts, and full texts, agreed study eligibility, and extracted information about study and participant characteristics, adverse event surveillance methodology, dihydroartemisinin-piperaquine exposures, loss-to-follow up, and any deaths after dihydroartemisinin-piperaquine treatment into a standardised database. The risk of sudden unexplained death after dihydroartemisinin-piperaquine with 95% credible intervals (CI) generated by Bayesian meta-analysis was compared with the baseline rate of sudden cardiac death. FINDINGS: Our search identified 94 eligible primary studies including data for 197 867 individuals who had received dihydroartemisinin-piperaquine: 154 505 in mass drug administration programmes; 15 188 in 14 studies of repeated courses in preventive therapies and case management of uncomplicated malaria; and 28 174 as single-course treatments of uncomplicated malaria in 76 case-management studies. There was one potentially drug-related sudden unexplained death: a healthy woman aged 16 in Mozambique who developed heart palpitations several hours after the second dose of dihydroartemisinin-piperaquine and collapsed and died on the way to hospital (no autopsy or ECG was done). The median pooled risk estimate of sudden unexplained death after dihydroartemisinin-piperaquine was 1 in 757 950 (95% CI 1 in 2 854 490 to 1 in 209 114). This risk estimate was not higher than the baseline rate of sudden cardiac death (0·7-11·9 per 100 000 person-years or 1 in 1 714 280 to 1 in 100 835 over a 30-day risk period). The risk of bias was low in most studies and unclear in a few. INTERPRETATION: Dihydroartemisinin-piperaquine was associated with a low risk of sudden unexplained death that was not higher than the baseline rate of sudden cardiac death. Concerns about repolarisation-related cardiotoxicity need not limit its current use for the prevention and treatment of malaria. FUNDING: Wellcome Trust, UK Medical Research Council, WHO, Bill & Melinda Gates Foundation, and University of Oxford.
引用
- Chan XHS, Win YN, Mawer LJ, et al. Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis. 2018. PMID: 29887371. doi:10.1016/S1473-3099(18)30297-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。